11th week of 2009 patent applcation highlights part 50 |
Patent application number | Title | Published |
20090069293 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION - This invention relates to novel lactams having the formula (I): | 2009-03-12 |
20090069294 | Organic Compounds - The present disclosure relates to XIAP inhibitor compounds of the formula I. | 2009-03-12 |
20090069295 | DEUTERIUM-ENRICHED CONIVAPTAN - The present application describes deuterium-enriched conivaptan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-12 |
20090069296 | 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them - Compounds of formula (I): | 2009-03-12 |
20090069297 | Aurora kinase modulators and method of use - The present invention relates to chemical compounds having a general formula I | 2009-03-12 |
20090069298 | Pyrazolo[1,5-A]Pyrimidine Compounds - The present invention relates to a novel pyrazolo[1,5-a]pyrimidine compound of the formula [I]: | 2009-03-12 |
20090069299 | Pyrazolo[3,4-c]Quinolines, Pyrazolo[3,4-c]Naphthyridines, Analogs Thereof, and Methods - Pyrazolo[3,4-c]quinolines, pyrazolo[4,5-c]naphthyridines, and analogs thereof, eg., 6,7,8,9-tetrahydro pyrazolo[3,4-c]quinolines, and, pharmaceutical compositions containing the compounds, intermediates, methods of making these compounds, and methods of use of these compounds as immunomodulators, for inhibiting cytokine biosynthesis in animals and in the therapeutic or prophylactic treatment of diseases by inhibiting cytokine biosynthesis are disclosed. | 2009-03-12 |
20090069300 | ISOQUINOLINYL AND ISOINDOLINYL DERIVATIVES AS HISTAMINE-3 ANTAGONISTS - The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor. | 2009-03-12 |
20090069301 | Acridine and Quinoline Derivatives as Sirtuin Modulators - Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, chemotherapeutic induced neuropathy, neuropathy associated with an ischemic event, polyglutamine diseases, ocular diseases and/or disorders, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent. | 2009-03-12 |
20090069302 | CHEMICAL COMPOUNDS - The present invention relates generally to novel therapeutic compounds and AXOR 109 agonists, and processes for the manufacture and use of the same. | 2009-03-12 |
20090069303 | PHTHALAZINONE DERIVATIVES - A compound of the formula (I): | 2009-03-12 |
20090069304 | MMP-13 SELECTIVE INHIBITOR - Since it is thought that if the activity of MMP-13 can be inhibited, this will largely contribute to improvement or prevention of progession of pathological states, particularly, osteoarthritis (OA), resulting from or associated with the MMP-13 activity, the development of MMP-13 inhibitors is anticipated. There are provided a compound represented by the general formula (I): | 2009-03-12 |
20090069305 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor - The present invention relates to substituted nitrogen-containing heteroaryl derivatives, pharmaceutical compositions containing them, and methods of using any of these derivatives and compositions for H | 2009-03-12 |
20090069306 | PROCESS FOR PRODUCING HIGHLY PURE MIDAZOLAM AND SALTS THEREOF - Provided is a process for producing highly pure midazolam and salts thereof, and a pharmaceutical composition containing the highly pure midazolam and/or a salt thereof. | 2009-03-12 |
20090069307 | Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions - The present invention relates to use of a pyridine compound of the following formula [I]: wherein R is a substituted pyridyl group having the following formula: R | 2009-03-12 |
20090069308 | Novel Use of Antihistamine Agents for the Preventive or Early Treatment of Inflammatory Syndromes, in Particular Those Triggered by Togaviruses - The present invention relates to the use of at least one antihistamine agent for the preparation of a medicament for use in the preventive or early treatment of inflammatory syndromes of viral origin, in particular arthritis of the distal joints, more particularly those triggered by togaviruses. The invention also relates to a combination product of at least one antihistamine agent and of at least one antiserotonin agent for its simultaneous, separate or sequential use in preventive or early therapy for inflammatory syndromes of viral origin, in particular arthritis of the distal joints, more particularly those triggered by togaviruses. | 2009-03-12 |
20090069309 | PROSTAGLANDIN ANALOGS - Compounds comprising | 2009-03-12 |
20090069310 | Anti-inflammatory medicaments - Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds. | 2009-03-12 |
20090069311 | 5-AMINOINDOLE DERIVATIVES AS H3 INVERSE AGONISTS - The present invention relates to compounds of formula I | 2009-03-12 |
20090069312 | Potassium Channel Inhibitors - The present invention relates to dipyridin-3-ylmethoxy compounds and derivatives thereof having the structure I useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like. | 2009-03-12 |
20090069313 | Novel MAO-A inhibitors - The present invention provides a new medical use for the compounds of the formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, as MAO-A inhibitors. Also included is a method for prophylaxis and treatment of mental disorders such as depression, in a mammal, comprising administering an effective amount of a compound of formula (I). These compounds are also effective in treating a disease, condition or disorder such as weight loss, obesity, bulimia, depression, bipolar disorders, psychoses, schizophrenia, behaviors, alcoholism, tobacco abuse, memory loss, Alzheimer's disease, dementia of aging, seizure disorders, epilepsy, attention deficit disorder, and Parkinson's disease, which is modulated by a cannabinoid receptor antagonist. | 2009-03-12 |
20090069314 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods - Certain imidazoquinolines with a hydroxymethyl or hydroxyethyl substituent at the 2-position, and an aryl or heteroaryl substituent at the 7-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for preferentially inducing IFN-α biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed. | 2009-03-12 |
20090069315 | Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders - The invention relates to methods of using the compounds of the invention, including pyrazolo[1,5a]pyrimidin-7-yl amine compounds and salts thereof, as well as pharmaceutical compositions comprising the same, in the treatment of Eph receptor-related (e.g., neurological) injuries and disorders. The invention also relates to modulating the activity of an Eph receptor in a cell, stimulating neural regeneration, and reversing neuronal degeneration, by administering a compound of the invention to a cell or subject in an effective amount. | 2009-03-12 |
20090069316 | NOVEL QUINOLINE DERIVATIVES - The invention relates to compounds represented by Formula (I): | 2009-03-12 |
20090069317 | Insecticidal Methods Using 3-Amino-1,2-Benzisothiazole Derivatives - The invention relates to insecticidal methods using 3-amino-1,2-benzoisothiazole compounds of the formula (I) wherein the variables n and R | 2009-03-12 |
20090069318 | Novel Compounds - Novel substituted 2,4,8-trisubstituted 8H-pyrido[2,3-d]pyrimidin-7-one containing compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors. | 2009-03-12 |
20090069319 | IMIDAZOPYRIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM - The present invention relates to imidazopyridine analogs, methods of making imidazopyridine analogs, compositions comprising an imidazopyridine analog, and methods for treating canonical Wnt-β-catenin cellular messaging system-related disorders comprising administering to a subject in need thereof an effective amount of an imidazopyridine analog. | 2009-03-12 |
20090069320 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof - Substituted 4-amino-quinazoline compounds corresponding to formula I | 2009-03-12 |
20090069321 | CYANOMETHYL SUBSTITUTED N-ACYL TRYPTAMINES - The present invention relates to cyanomethyl substituted N-acyl tryptamines of the formula I | 2009-03-12 |
20090069322 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BACTERIAL POLYPEPTIDE FORMYLASE FOR TREATING MICROBIAL INFECTIONS - Compounds of formula (I) are antibacterial or antiprotozoal agents for treatment of infections in humans and non-human mammals, wherein: Z represents a radical of formula —N(OH)CH(═O) or formula C(═O)NH(OH); R | 2009-03-12 |
20090069323 | 11beta-hsdi inhibitors - The invention relates to compounds of formula (I) | 2009-03-12 |
20090069324 | CHEMICAL INHIBITORS OF BFL-1 AND RELATED METHODS - Compounds that bind to Bfl-1 as well as conjugates of such compounds are provided. Various embodiments additionally provide methods of using such compounds to identify additional anti-apoptotic Bfl-1 binding compounds. Methods of using such compounds to increase apoptosis in a cell are also provided. | 2009-03-12 |
20090069325 | Piperidine Derivatives Useful as Modulators of Chemokine Receptor Activity - The present invention relates to the compounds of formula (I): | 2009-03-12 |
20090069326 | SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 - The present invention discloses novel compounds of Formula I: (I) possessing 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11β-HSD type 1 activity. | 2009-03-12 |
20090069327 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS - The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, Bmx, b-RAF, c-RAF, c-SRC, KDR, CSK, FGFR3, JAK2, Lck, Met, PKCα, SAPK2α, Tie2, TrkB and P70S6K kinases. | 2009-03-12 |
20090069328 | ALPHA-ALKYL SUBSTITUTED N-ACYLTRYPTOPHANOLS - The present invention relates to α-alkyl substituted N-acyltryptophanols of the formula I | 2009-03-12 |
20090069329 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY - The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders. | 2009-03-12 |
20090069330 | Substituted Oxazole Compounds with Analgesic Activity - Substituted oxazole derivatives corresponding to formula 1: | 2009-03-12 |
20090069331 | GUANIDINE DERIVATIVES AS INHIBITORS OF DDAH - Compounds of formula (I) have been found to be useful as inhibitors of DDAH. The present invention thus provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a disease whose pathology is affected by DDAH | 2009-03-12 |
20090069332 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS - This invention relates to pyridazine derivatives represented by the formula (1): | 2009-03-12 |
20090069333 | FUNGICIDES - This invention relates to novel derivatives of pyridopyrazines and pyridopyridazines, to processes for preparing them, to intermediate chemicals used in their manufacture, to compositions containing them and to methods of using them to combat fungi, especially fungal infections of plants. The fungicidal compounds have the general formula (1) wherein R, R | 2009-03-12 |
20090069334 | Pyridazine based alpha-helix mimetics - The synthesis of new α-helix scaffolds mimicking i, i+3 or i+4, i+7 residues, was accomplished. The common pyridazine heterocycle originates from the easily available building block, 6. These scaffolds may be thought of as synthetic counterparts of amphiphilic α-helices having a “wet face” along one side and a hydrophobic face along the other side of the helix. | 2009-03-12 |
20090069335 | Guanidine-containing compounds useful as muscarinic receptor antagonists - The invention provides compounds of formula I: | 2009-03-12 |
20090069336 | PYRIMIDOTHIOPHENE COMPOUNDS - Compounds of formula (I) are inhibitors of HSP90, and useful in the treatment of, for example, cancers: | 2009-03-12 |
20090069337 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY - The present disclosure provides compounds having affinity for the 5-HT | 2009-03-12 |
20090069338 | Method for predicting skin sensitizing activity of compounds - Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, methods of using compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions comprising compounds exhibiting ATP-utilizing enzyme inhibitory activity, are disclosed. | 2009-03-12 |
20090069339 | DEUTERIUM-ENRICHED CIPROFLOXACIN - The present application describes deuterium-enriched ciprofloxacin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-12 |
20090069340 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders - Compounds of Formula (I), wherein R | 2009-03-12 |
20090069341 | INHIBITORS OF HSP90 - The invention relates to the use of benzoimidazolone compounds and salts thereof in the treatment of proliferative diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, pharmaceutical preparations comprising benzoimidazolone compounds, novel benzoimidazolone compounds, and a process for the preparation of the novel benzoimidazolone compounds. | 2009-03-12 |
20090069342 | KV1.5 POTASSIUM CHANNEL INHIBITORS - The present invention relates to 1-N-amino-2-imidazolidinones and derivatives thereof which are effective as Kv1.5 potassium channel inhibitors providing atrial-selective antiarrhythmic agents. The present invention further relates to compositions comprising said Kv1.5 potassium channel inhibitors, and to methods for treating cardiac arrhythmia. | 2009-03-12 |
20090069343 | Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus - Patients suffering from pruritus or itch may be effectively treated by administering a centrally acting histamine H1 receptor antagonist (e.g., diphenhydramine, triprolidine, hydroxyzine, pyrilamine, promethazine, or chlorpheniramine) and a histamine H4 receptor antagonist (e.g., 5-chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone). | 2009-03-12 |
20090069344 | Modulators of hcv replication - The present invention is directed to compounds of formula (I): | 2009-03-12 |
20090069345 | Pharmaceutically Stable Compound Consisting of Timolol, Dorzolamide and Brimonidine - The present invention is related to ophthalmic formulations for the treatment of ocular ailments. More specifically, it is related to the pharmaceutical industry in the production of ophthalmic medication for the treatment of ocular hypertension. The advantage of the present invention over other state of the art treatments is that it achieves a composition of Dorzolamide Hydrochloride, Timolol Maleate and Brimonidine Tartrate with excellent properties of stability; it does not give rise to chemical reactions which produce modifications in the active molecules; with no antagonistic effects among the components. The present invention consists of a stable pharmaceutical composition for the treatment of ocular hypertension characterized by consisting of the following excipients: Polyoxyl 40 Stearate, Sodium Borate crystals, Sodium Chloride, Mannitol and Benzalkonium chloride. | 2009-03-12 |
20090069346 | SOLID HERBICIDAL COMPOSITION - To provide a solid herbicidal composition in which decomposition of the herbicidal active ingredient is suppressed, and favorable herbicidal activity is stably exhibited. A solid herbicidal composition comprising (1) 1-(4,6-dimethoxypyrimidin-2-yl)-3-(3-trifluoromethyl-2-pyridylsulfonyl)urea or its salt and (2) at least one surfactant selected from the group consisting of a naphthalene sulfonate condensed with formaldehyde, an alkylnaphthalene sulfonate condensed with formaldehyde, a dialkylnaphthalene sulfonate condensed with formaldehyde and a polycarboxylate. | 2009-03-12 |
20090069347 | 2-phenoxy pyrimidinone analogues - 2-Phenoxy pyrimidinone analogues are provided, of the Formula: | 2009-03-12 |
20090069348 | Use of Inhibitors of the Renin-Angiotensin System - It has been found that an inhibitor of the renin-angiotensin system is useful for the treatment or prevention of a condition associated with hypoxia or impaired metabolic function or efficiency. In particular, it may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and is thus useful in treatment of the symptoms and signs of ageing. It may also be used to enhance function in healthy subjects. | 2009-03-12 |
20090069349 | DEUTERIUM-ENRICHED PEMETREXED - The present application describes deuterium-enriched pemetrexed, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-12 |
20090069350 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF - The present invention relates to pharmaceutical compositions and dosage compositions of compounds, including injectable formulations for the parenteral delivery of such compounds into patients in need of such treatment. Also featured are methods of making and using the compositions, including methods for the treatment of neoplastic diseases. | 2009-03-12 |
20090069351 | DEUTERIUM-ENRICHED BOSENTAN - The present application describes deuterium-enriched bosentan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-12 |
20090069352 | DEUTERIUM-ENRICHED CLAZOSENTAN - The present application describes deuterium-enriched clazosentan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-12 |
20090069353 | DEUTERIUM-ENRICHED AMBRISENTAN - The present application describes deuterium-enriched ambrisentan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-12 |
20090069354 | DEUTERIUM-ENRICHED GEMCITABINE - The present application describes deuterium-enriched gemcitabine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-12 |
20090069355 | Bicyclic pyrazolone cytokine inhibitors - The present invention relates to 6,7-dihydro-5H-pyrazolo[1,2a]pyrazol-1-ones which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said 6,7-dihydro-5H-pyrazolo[1,2a]pyrazol-1-ones and methods for preventing, abating, or otherwise controlling enzymes which are understood to be the active components responsible for the herein described disease states. | 2009-03-12 |
20090069356 | USE OF ANILINOPYRIMIDINES IN WOOD PROTECTION - The present invention relates to the use of the anilinopyrimidines pyrimethanil, cyprodinil and mepanipyrim for the protection of wood and wood materials against wood destroying and wood discolouring fungi. | 2009-03-12 |
20090069357 | DEUTERIUM-ENRICHED ICLAPRIM - The present application describes deuterium-enriched iclaprim, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-12 |
20090069358 | Use of IKappaB-Kinase Inhibitors in Pain Therapy - The present invention relates to the use of IκB-kinase Inhibitors and methods for the prophylaxis and therapy for treating pain comprising administering such compounds. | 2009-03-12 |
20090069359 | Topical and transdermal treatments using urea formulation - Various medical conditions, some previously treated by injection or surgery, are effectively treated by a topical application of a composition of urea and a chemotherapeutic agent. Such agents include sclerosing agents, vasodilators, botulinum toxin and minoxidil. Conditions as diverse as spider veins, erectile dysfunction, facial wrinkles, hair loss and baldness can be effectively treated with the compositions. | 2009-03-12 |
20090069360 | Organic Compounds - The present invention relates to the discovery that certain compounds inhibit, regulate and/or modulate tyrosine and serine/threonine kinase and kinase-like proteins, such as RAF kinase, a serine/threonine kinase that functions in the MAP kinase signaling pathway, and is concerned with compositions which contain these compounds, and methods of using them to treat tyrosine and serine/threonine kinase and kinase-like dependent diseases, such as angiogenesis, cancer and cardiac hypertrophy. | 2009-03-12 |
20090069361 | METHODS OF TREATMENT USING (+)- ISOPROPYL 2-METHOXYETHYL 4-(2-CHLORO-3-CYANO-PHENYL)-1, 4-DIHYDRO-2, 6-DIMETHYL-PYRIDINE-3, 5-DICARBOXYLATE - The present invention relates to methods of treatment using the compound (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate, as a sole active agent or in combination with other pharmacological agents. | 2009-03-12 |
20090069362 | Novel Spiro-benzo[c]chromene derivatives useful as modulators of the estrogen receptors - The present invention is directed to novel spiro-benzo[C]chromene derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders mediated by one or more estrogen receptors. The compounds of the invention are useful in the treatment of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist. | 2009-03-12 |
20090069364 | PHARMACEUTICAL COMPOSITIONS OF 5-ALPHA-REDUCTASE INHIBITORS AND METHODS OF USE THEREOF - Non-occlusive compositions for transdermal delivery of 5-alpha-reductase inhibitors, and more particularly finasteride or dutasteride or pharmaceutically acceptable salts or derivatives thereof, and methods of making same. The composition may, for example, be a gel suitable for transdermal or transmucosal applications. The compositions of the present invention typically include a mixture of water and alcohol, and a solvent system having a mono alkyl ether of diethylene glycol and a glycol present in specified ratios and in specific amounts, wherein the pH of the gel is usually between about pH 4.5 and about pH 8. The compositions may include further components, for example, the hydroalcoholic vehicle may further include additional penetration enhancer(s), buffering agent(s), antioxidant(s), stabilizer(s) and/or gelling agent(s). Also, a method for the sustained delivery of 5-alpha-reductase inhibitors to treat a variety of conditions and disorders. | 2009-03-12 |
20090069365 | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators - The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity). | 2009-03-12 |
20090069366 | DEUTERIUM-ENRICHED TACROLIMUS - The present application describes deuterium-enriched tacrolimus, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-12 |
20090069367 | METHODS FOR TREATMENT OF CANCER - A method for treating or preventing cancer in a subject comprising administering a treatment effective amount of a chemotype 4 compound. | 2009-03-12 |
20090069368 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS - FGF receptor agonist compounds corresponding to the general formula: M1-L-M2 are disclosed in which M1 and M2, which may be identical or different, each represent, independently of one another, a monomer unit M, and L represents a linker group, wherein the monomer unit is of the general formula I. | 2009-03-12 |
20090069369 | DEUTERIUM-ENRICHED PRASUGREL - The present application describes deuterium-enriched prasugrel, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-12 |
20090069370 | AZACYCLYLISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS - The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor. | 2009-03-12 |
20090069371 | ISOQUINOLINE COMPOUNDS - Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided. | 2009-03-12 |
20090069372 | ANTITUMOR AGENTS - The invention provides compounds of formula I: | 2009-03-12 |
20090069373 | Quinoline Acids - This invention relates generally to quinoline-based modulators of Liver X receptors (LXRs) and related methods. | 2009-03-12 |
20090069374 | Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments - The invention provides novel 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including but not limited to depression and anxiety. | 2009-03-12 |
20090069375 | DEUTERIUM-ENRICHED MIGLUSTAT - The present application describes deuterium-enriched miglustat, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-12 |
20090069376 | VLA-4 Antagonists - Substituted N—[N-(sulphonylphenyl)sulfonyl-prolyl]-phenylalanine derivatives of the present invention are antagonists of the VLA-4 integrin and are useful in the treatment, prevention and suppression of diseases mediated by VLA-4-binding and cell adhesion and activation. Moreover, the compounds of the present invention demonstrate significant receptor occupancy of VLA-4 bearing cells after oral administration and are suitable for once-, twice-, or thrice-a-day oral administration. This invention also relates to compositions containing such compounds and methods of treatment using such compounds. | 2009-03-12 |
20090069377 | DEUTERIUM-ENRICHED ENZASTAURIN - The present application describes deuterium-enriched enzastaurin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-12 |
20090069378 | DEUTERIUM-ENRICHED DONEPEZIL - The present application describes deuterium-enriched donepezil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-12 |
20090069379 | DEUTERIUM-ENRICHED LENALIDOMIDE - The present application describes deuterium-enriched lenalidomide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-12 |
20090069380 | DEUTERIUM-ENRICHED AROXIFENE - The present application describes deuterium-enriched arzoxifene, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-12 |
20090069381 | DEUTERIUM-ENRICHED RALOXIFENE - The present application describes deuterium-enriched raloxifene, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-12 |
20090069382 | Bicyclic Angiotensin II Agonists - There is provided a compound of formula I, | 2009-03-12 |
20090069383 | Thrombin Receptor Antagonists - A series of compounds represented by the structural formulas | 2009-03-12 |
20090069384 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION - There is provided compounds of formula I: wherein the dotted lines, U5 V5 X | 2009-03-12 |
20090069385 | Antidiabetic Oxazolidinediones and Thiazolidinediones - Pyridinyloxyphenyl and pyridinyloxybenzyl oxazolidine-2,4-diones and thiazolidine-2,4-diones are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes. | 2009-03-12 |
20090069386 | Liquid Composition, Process for Producing the Liquid Composition,and Ectoparasite Controlling Agent for Use in Mammals and Avians - A liquid composition comprising (a) 21 to 70 parts by weight of a solvent having no nitrogen atom and having a carbonyl or sulfonyl group in the molecule, (b) 30 to 78.9 parts by weight of at least one component selected from the group consisting of a non-cyclic alcohol, an alkylene glycol, a polyalkylene glycol, a triol, a glycol monoacetate and a glycol monoalkyl ether, (c) 0.001 to 30 parts by weight of a physiologically active ingredient, and (d) 0.001 to 49 parts by weight of water. | 2009-03-12 |
20090069387 | ANIMAL PARASITE-CONTROL METHOD USING INSECT GROWTH REGULATORS - Methods and formulations for treating animal ectoparasites, effective against parasites such as fleas and ticks are provided. The methods comprise topically co-administering a non-mobile insect growth regulator, a mobile insect growth regulator, and an adulticide to the animal. Parasiticidal formulations for treating animal ectoparasites are also provided, which can be safe to use and avoids the many common deleterious side effects of conventional topical formulations. The topical formulations comprise a combination of two insect growth regulators and an additional insecticide. The topical formulation can be packaged together or packaged so that active components are stored separately prior to administering the topical insecticide formulation to the animal. | 2009-03-12 |
20090069388 | DEUTERIUM-ENRICHED SORAFENIB - The present application describes deuterium-enriched sorafenib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-12 |
20090069389 | NOVEL CONTROLLED RELEASE-NIACIN FORMULATION - The present invention relates to a controlled-release niacin formulation. In particular, the present invention relates to a controlled-release niacin formulation, comprising niacin; hydroxypropyl methylcellulose; and a carboxyvinyl polymer, in which the carboxyvinyl polymer and hydroxypropyl methylcellulose are contained in a predetermined weight ratio, and to a preparation method thereof. | 2009-03-12 |
20090069390 | DEUTERIUM-ENRICHED RUFINAMIDE - The present application describes deuterium-enriched rufinamide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-12 |
20090069391 | Benzothiophene hydroxamic acid derivatives - The present invention relates to a novel class of hydroxamic acid derivatives. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo. | 2009-03-12 |
20090069392 | COMPOSITION THAT PREVENTS DAMAGE TO TREES BY HARMFUL INSECTS AND A PREVENTION METHOD THEREOF - The present invention relates to a composition comprising a neonicotinoid-based compound having a high degree of insecticidal activity, a surfactant, and an organic solvent, which is capable of demonstrating stable effects and in which the types and amounts of surfactant and organic solvent are adjusted so as to prevent chemical damage in numerous types of trees. In addition, the present invention relates to a method for preventing damage to trees by harmful insects of numerous types of trees by injecting this composition into a tree trunk and allowing the chemical to circulate within the tree body. | 2009-03-12 |
20090069393 | PARENTERAL FORMULATION FOR EPOTHILONE ANALOGS - A process for formulating certain epothilone analogs for parenteral administration is disclosed wherein the analog is dissolved in a mixture of at least | 2009-03-12 |